GT201500292A - Formas cristalinas de inhibidores de tirosina cinasa y sus sales - Google Patents

Formas cristalinas de inhibidores de tirosina cinasa y sus sales

Info

Publication number
GT201500292A
GT201500292A GT201500292A GT201500292A GT201500292A GT 201500292 A GT201500292 A GT 201500292A GT 201500292 A GT201500292 A GT 201500292A GT 201500292 A GT201500292 A GT 201500292A GT 201500292 A GT201500292 A GT 201500292A
Authority
GT
Guatemala
Prior art keywords
salts
tyrosine kinase
kinase inhibitors
crystalline forms
same
Prior art date
Application number
GT201500292A
Other languages
English (en)
Inventor
Jay Jie-Qiang Wu
Ling Wang
Original Assignee
Vm Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vm Pharma Llc filed Critical Vm Pharma Llc
Publication of GT201500292A publication Critical patent/GT201500292A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A VARIAS FORMAS POLIMÓRFICAS Y FORMA AMORFA DE 4-((3-(4-CICLOHEXILPIPERAZIN-1-IL)-6-OXO-6H-ANTRAL[1, 9 -CD] ISOXAZOL-5-IL)AMMINO)BENZATO DE SODIO, QUE INCLUYE LA FORMA POLIMÓRFICA A, MEZCLAS DE LOS POLIMORFOS, PROCESOS PARA LA PREPARACIÓN DE LOS MISMOS Y EL USO DE LOS MISMOS EN UNA COMPOSICIÓN FARMACÉUTICA QUE CONTIENE A LOS MISMOS.
GT201500292A 2013-03-15 2015-09-14 Formas cristalinas de inhibidores de tirosina cinasa y sus sales GT201500292A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361801112P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
GT201500292A true GT201500292A (es) 2019-07-29

Family

ID=51529961

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201500292A GT201500292A (es) 2013-03-15 2015-09-14 Formas cristalinas de inhibidores de tirosina cinasa y sus sales

Country Status (23)

Country Link
US (5) US8999992B2 (es)
EP (1) EP2970148A4 (es)
JP (1) JP2016513704A (es)
KR (1) KR20150142688A (es)
CN (1) CN105377821A (es)
AU (1) AU2014239254B2 (es)
BR (1) BR112015022631A2 (es)
CA (1) CA2904403A1 (es)
CL (1) CL2015002593A1 (es)
CR (1) CR20150560A (es)
EA (1) EA201591684A1 (es)
GT (1) GT201500292A (es)
HK (1) HK1220193A1 (es)
MX (1) MX2015012403A (es)
NI (1) NI201500139A (es)
PE (1) PE20151884A1 (es)
PH (1) PH12015502110A1 (es)
SG (2) SG10201707484UA (es)
SV (1) SV2015005074A (es)
TN (1) TN2015000407A1 (es)
UA (1) UA116466C2 (es)
WO (1) WO2014152663A1 (es)
ZA (1) ZA201507154B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0922224A2 (pt) 2008-12-08 2016-08-02 Vm Pharma Llc composições de inibidores de proteína tirosina quiinase receptora.
US8999992B2 (en) 2013-03-15 2015-04-07 Vm Pharma Llc Crystalline forms of tryosine kinase inhibitors and their salts
US10301271B2 (en) * 2014-09-17 2019-05-28 Purdue Pharma L.P. Crystalline forms of tyrosine kinase inhibitors and their salts
US20180370926A1 (en) * 2015-08-07 2018-12-27 Purdue Pharma L.P. Process of preparing tyrosine kinase inhibitor
AU2018350980B2 (en) 2017-10-18 2023-02-23 Incyte Corporation Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors
WO2019159097A1 (en) * 2018-02-14 2019-08-22 Sun Pharmaceutical Industries Limited Crystalline polymorphic forms of acalabrutinib
LT3847175T (lt) 2018-09-05 2024-03-25 Incyte Corporation Fosfoinozitido 3-kinazės (pi3k) inhibitoriaus kristalinės formos
EP4153564A4 (en) 2020-05-19 2024-06-19 Cybin IRL Limited DEUTERATED TRYPTAMINE DERIVATIVES AND METHODS OF USE

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1062357A (en) * 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
US4337341A (en) * 1976-11-02 1982-06-29 Eli Lilly And Company 4a-Aryl-octahydro-1H-2-pyrindines
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
RU2065438C1 (ru) 1993-12-22 1996-08-20 Институт химии природного органического сырья СО РАН Способ получения производных 3-фенилокси-5-гидроксиантра (1,9-cd)-изоксазол-6-она
US6635626B1 (en) 1997-08-25 2003-10-21 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
US5998463A (en) 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors
US6476032B2 (en) 1998-12-17 2002-11-05 Wyeth 2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)one derivatives
WO2000075139A2 (en) 1999-06-03 2000-12-14 Basf Aktiengesellschaft Benzothiazinone and benzoxazinone compounds
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
JP2005508337A (ja) 2001-09-27 2005-03-31 スミスクライン ビーチャム コーポレーション 化合物
KR20030095729A (ko) 2002-06-14 2003-12-24 크리스탈지노믹스(주) 2-[5-(3-카복시-4-클로로-페닐)-푸란-2-일메틸렌]-3-옥소-2,3-디하이드로-5Ｈ-티아졸로[3,2-ａ]피리미딘-6-카복실산에틸 에스테르 유도체를 포함하는 단백질 티로신포스파타제 1Ｂ 활성 억제용 약학 조성물
WO2004032870A2 (en) 2002-10-08 2004-04-22 Rinat Neuroscience Corp. Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
IL154370A0 (en) * 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
ES2386161T3 (es) 2003-04-16 2012-08-10 Bristol-Myers Squibb Company Proceso para separar una mezcla de enantiómeros de éster alquílico usando una enzima
US8362264B2 (en) 2003-08-22 2013-01-29 Dendreon Corporation Compositions and methods for the treatment of disease associated with Trp-p8 expression
WO2008021463A2 (en) 2006-08-15 2008-02-21 Acadia Pharmaceuticals, Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
HUE037549T2 (hu) 2004-04-07 2018-09-28 Rinat Neuroscience Corp Eljárások csontrákfájdalom kezelésére idegi növekedési faktor antagonista antitest beadásával
WO2006007864A1 (en) 2004-07-17 2006-01-26 Max Planck Geselllschaft Zur Förderung Der Wissenschaft Treating neurodegenerative conditions
US7671077B2 (en) * 2004-07-19 2010-03-02 Leu-Fen Hou Lin Neuroprotective small organic molecules, compositions and uses related thereto
WO2006036936A2 (en) 2004-09-27 2006-04-06 Bridge Pharma, Inc. The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
JP5201995B2 (ja) 2005-01-19 2013-06-05 エーザイ インク． ジアザベンゾ［デ］アントラセン−３−オン化合物、及び、ｐａｒｐの阻害方法
FR2881138B1 (fr) 2005-01-27 2007-03-02 Servier Lab Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20060257337A1 (en) 2005-04-28 2006-11-16 David Sherris Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
JP5191155B2 (ja) 2006-03-27 2013-04-24 大塚製薬株式会社 カルボスチリル化合物からなる医薬
JP2007303392A (ja) 2006-05-11 2007-11-22 Honda Motor Co Ltd 気体燃料内燃機関の制御装置
WO2008053863A1 (fr) 2006-10-30 2008-05-08 Santen Pharmaceutical Co., Ltd. Nouveau composé ayant un squelette de 1,4-benzothiazin-3-one ou un squelette de 3,4-dihydroquinolin-2-one
WO2008082887A2 (en) 2006-12-28 2008-07-10 Abbott Laboratories Inhibitors of poly(adp-ribose)polymerase
EP2218713A1 (en) 2007-08-17 2010-08-18 Hetero Drugs Limited Erlotinib hydrochloride polymorph Form A substantially free of polymorph Form B
KR101192231B1 (ko) 2007-11-16 2012-10-17 홀린워스 펀드, 엘.엘.씨. 메타물질 구조에 기반한 필터 및 필터 설계 방법
BRPI0922224A2 (pt) 2008-12-08 2016-08-02 Vm Pharma Llc composições de inibidores de proteína tirosina quiinase receptora.
EP2239256A1 (en) * 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
WO2011063398A1 (en) * 2009-11-23 2011-05-26 Cylene Pharamaceuticals, Inc. Polymorphs and salts of a kinase inhibitor
CA2796192A1 (en) 2010-06-23 2011-12-29 OSI Pharmaceuticals, LLC Polymorphs of osi-906
AR084824A1 (es) 2011-01-10 2013-06-26 Intellikine Inc Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
US9376406B2 (en) 2011-03-03 2016-06-28 Indiana University Research And Technology Corporation uPAR-uPA interaction inhibitors and methods for treating cancer
US8999992B2 (en) * 2013-03-15 2015-04-07 Vm Pharma Llc Crystalline forms of tryosine kinase inhibitors and their salts
US10301271B2 (en) 2014-09-17 2019-05-28 Purdue Pharma L.P. Crystalline forms of tyrosine kinase inhibitors and their salts

Also Published As

Publication number Publication date
PH12015502110A1 (en) 2016-01-11
KR20150142688A (ko) 2015-12-22
US20140275113A1 (en) 2014-09-18
SG11201507516XA (en) 2015-10-29
CR20150560A (es) 2016-08-31
EA201591684A1 (ru) 2016-02-29
US9993473B2 (en) 2018-06-12
HK1220193A1 (zh) 2017-04-28
US9388146B2 (en) 2016-07-12
EP2970148A4 (en) 2016-10-12
NI201500139A (es) 2016-02-16
ZA201507154B (en) 2017-09-27
JP2016513704A (ja) 2016-05-16
CA2904403A1 (en) 2014-09-25
CL2015002593A1 (es) 2016-08-19
PE20151884A1 (es) 2016-01-08
CN105377821A (zh) 2016-03-02
TN2015000407A1 (en) 2017-01-03
US20150174124A1 (en) 2015-06-25
UA116466C2 (uk) 2018-03-26
US9718794B2 (en) 2017-08-01
US20160002182A1 (en) 2016-01-07
BR112015022631A2 (pt) 2017-12-19
AU2014239254A1 (en) 2015-10-15
US20170105990A1 (en) 2017-04-20
WO2014152663A1 (en) 2014-09-25
SV2015005074A (es) 2017-07-19
US20180057469A1 (en) 2018-03-01
MX2015012403A (es) 2016-04-04
US20170001969A9 (en) 2017-01-05
US10124002B2 (en) 2018-11-13
US8999992B2 (en) 2015-04-07
EP2970148A1 (en) 2016-01-20
SG10201707484UA (en) 2017-10-30
AU2014239254B2 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
GT201500292A (es) Formas cristalinas de inhibidores de tirosina cinasa y sus sales
CR20150629A (es) Compuestos químicos
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CY1122222T1 (el) Συνθεση βορονικων αλατων και χρησεις αυτων
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
ECSP18092481A (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
CR20160099A (es) Formulación de inhibidores de la syk
DOP2015000196A (es) Amidas heterocíclicas como inhibidores de cinasas
BR112018015880A2 (pt) forma cristalina a de agonista de tlr7, método de preparação e uso da mesma
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
NI201500096A (es) Compuesto químicos
DK3003038T3 (da) 2h-1,2,3-triazolderivater som inhibitorer af fibrose
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
ECSP16074478A (es) Compuestos novedosos
CR20160400A (es) Derivados de nucleosido sustituidos con 4´-difluorometilo como inhibidores de la replicación de arn de la influenza
UY36166A (es) Formas de sales de n—(cianometil)—4—(2—(4—morfolinofenilamino)pirimidin—4—il)benzamida, sus composiciones y su uso terapeutico
CL2018002089A1 (es) Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso
CL2016001172A1 (es) Nuevos inhibidores de dgat2.
CL2017000682A1 (es) Compuestos novedosos de imidazopiridazina y su uso.
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
CR20160016A (es) Pirazolpiridinas sustituidas
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
CR20160494A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
EA201600123A1 (ru) Производные 1-(пиперазин-1-ил)-2-([1,2,4]триазол-1-ил)этанона